IL-6 have been demonstrated to regulate the self-renewal in breast CSCs [30, 31], triggering malignant features in ductal breast carcinoma [31] and mediating drug resistance in breast cancer cells by expanding CSC population [32]. Here, IL6 is linked to breast carcinoma.